DUSA Announces Resignation of Officer.WILMINGTON, Mass. -- DUSA DUSA Deputy Under Secretary of the Army DUSA Deakin University Student Association DUSA Dundee University Students' Association (Scotland) DUSA Designated Unclassified Subject Area Pharmaceuticals, Inc. (NASDAQ NASDAQ in full National Association of Securities Dealers Automated Quotations U.S. market for over-the-counter securities. Established in 1971 by the National Association of Securities Dealers (NASD), NASDAQ is an automated quotation system that reports on NMS See NetWare Management System. :DUSA) today announced that Gary Talarico, VP of Sales, had resigned for personal reasons on July 9, 2005. The resignation will be effective July 22, 2005. Mr. Talarico joined DUSA on February 16, 2005 after serving DUSA as a consultant for several months. Bob Doman, DUSA's President and COO, stated "We want to thank Gary for his insight, guidance and significant contributions as we built up our sales team and began to implement our current sales strategies. We wish him well as he resumes his consulting practice. For the immediate future, David Page David Page may refer to:
DUSA Pharmaceuticals, Inc. is a biopharmaceutical company engaged primarily in the development of Levulan Photodynamic Therapy photodynamic therapy n. A type of phototherapy in which a nontoxic light-sensitive compound that has been injected into a patient is exposed selectively to light, whereupon it becomes toxic to targeted malignant and other diseased cells. (PDT PDT abbr. Pacific Daylight Time PDT Pacific Daylight Time PDT n abbr (US) (= Pacific Daylight Time) → hora de verano del Pacífico PDT ) and Photodetection (PD) for multiple medical conditions, with its primary focus in dermatology. PDT and PD utilize light-activated compounds to induce a therapeutic or detection effect. DUSA maintains offices in Wilmington, MA, Valhalla, NY and Toronto, Ontario. Except for historical information, this news release contains certain forward-looking statements that involve known and unknown risks and uncertainties, which may cause actual results to differ materially from any future results, performance or achievements expressed or implied by the statements made. These forward-looking statements relate to beliefs concerning the effective date of Mr. Talarico's resignation and the responsibilities of Mr. Page for the immediate future. Such risks and uncertainties include, but are not limited to, the Company's ability to effectuate the resignation of Mr. Talarico in a timely manner, the continuing service to the Company by Mr. Page, and other risks identified in our SEC filings from time to time, including those contained in DUSA's Form 10-K Form 10-K A report required by the SEC from exchange-listed companies that provides for annual disclosure of certain financial information. Form 10-K See 10-K. for the year ended December 31, 2004. DUSA Pharmaceuticals, Inc. (NASDAQ:DUSA) |
|
||||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion